Australian Therapeutic Goods Administration provisionally approves Moderna for kids aged 6-11
Australian Therapeutic Goods Administration provisionally approves Moderna for kids aged 6-11
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
The Therapeutic Goods Administration (TGA) has provisionally approved the Moderna COVID-19 vaccine, SPIKEVAX, for use in individuals aged 6 years and older. As for other age groups, the use of this vaccine in children aged 6-11 years should be administered as 2 doses at least 28 days apart, though a lower dose will be given. Below, Aussie researchers comment on the announcement.
The Therapeutic Goods Administration (TGA) has provisionally approved the Moderna COVID-19 vaccine, SPIKEVAX, for use in individuals aged 6 years and older. As for other age groups, the use of this vaccine in children aged 6-11 years should be administered as 2 doses at least 28 days apart, though a lower dose will be given. Below, Aussie researchers comment on the announcement.
Publication
What our experts say
Context and background
Resources
Expert Comments:
Dr Roger Lord
The provisional approval of the Moderna COVID-19 vaccine for use in children 6 years and older is welcome news.
The spread of the virus happens in the early stages of an infection well before the individual becomes significantly unwell.
Children regularly mix in schools and if unprotected will serve as a reservoir of on-going infection and a potential source of new variants over time.
Four factors are critical to arresting hospitalisation and severe illness which include the evolution of the virus, vaccination rates, preventative measures (e.g. social distancing, improved ventilation) and improvements in COVID-19 treatments.
Vaccination of school age children will help to decrease infection rates in a substantial section of the population.
Associate Professor Paul Griffin
As we’ve seen with so many other approvals in recent times, the announcement of the approval of the Moderna mRNA vaccine “spikevax” today for children aged 6 to 11 years of age is more welcome news. The data supporting its use is clear with a large study of around 4000 children in this age group conducted in the USA and Canada demonstrating high rates of both efficacy and safety.
This of course is in addition to this vaccine being successfully used in our country and many others, in older children and adults, as well as the successful use of the other mRNA vaccine produced by Pfizer in children down to five years of age here in Australia already. While it has been pleasing to see many children in the 5 to 11 year age range already come out and receive their vaccine (my three children included), the uptake in this age range in our country is still less than 50 per cent.
With school (very appropriately) going back and the transmission we have seen in this age group in recent times, the importance of comprehensive (yet reasonable) mitigation strategies including vaccination has been highlighted. Adding another safe and effective vaccine option should hopefully help further increase uptake in this age group.
